Table 1.
Caco2 | |||
---|---|---|---|
Tetrapyrrole (μM) | % tail DNA±SD | % tail DNA pos control±SD | % tail DNA neg control±SD |
BR 0.5 | 18.7±3p | 36.5±4 | 21.3±3 |
BR 5 | 21.3±3.8p | ||
BR 17 | 13.8±1.9np | ||
BRDT 0.5 | 10.8±2.6np | 29.1±2.7 | 7.7±2.0 |
BRDT 5 | 11.7±2.6p | ||
BRDT 17 | 18.2±4.1p | ||
BR-DME 0.5 | 8.7±2.7 | 21.9±3.9 | 9.9±4.0 |
BR-DME 5 | 11.5±2.3p | ||
BR-DME 17 | 15.0±6.9p | ||
BV 0.5 | 20.9±4.3p | 30.1±5.0 | 16.5±2.6 |
BV 5 | 20.8±2 | ||
BV 17 | 18.4±2.7 | ||
BV-DME 0.5 | 15.6±3.5p | 26.6±2.9 | 15.5±2.5 |
BV-DME 5 | 15.3±3.2p | ||
BV-DME 17 | 12.9±2.2p | ||
HepG2 | |||
Tetrapyrrole | % tail DNA±SD | % tail DNA pos control±SD | % tail DNA neg control±SD |
BR 0.5 | 10.8±2.8 | 18.5±3.9 | 9.3±1.0 |
BR 5 | 9.2±2.9 | ||
BR 17 | 9.7±1.3 | ||
BRDT 0.5 | 8.2±0.8p | 13.3±0.9 | 7.4±2.0 |
BRDT 5 | 8.8±1.4p | ||
BRDT 17 | 8.5±1.1p | ||
BR-DME 0.5 | 8.8±2.5p | 13.4±2.5 | 6.8±2.3 |
BR-DME 5 | 9.3±1.3p | ||
BR-DME 17 | 8.7±2.5 | ||
BV 0.5 | 17.2±1.4n | 16.8±0.7 | 12.3±1.0 |
BV 5 | 15.1±0.9np | ||
BV 17 | 16.6±1.3n | ||
BV-DME 0.5 | 17.0±2.2np | 21.6±2.1 | 12.3±1.6 |
BV-DME 5 | 14.6±2.0p | ||
BV-DME 17 | 17.8±1.4np |
- p: significantly different to positive control (p≤0.05).
- n: significantly different to negative control (p≤0.05).
- np: significantly different to negative and positive controls (p≤0.05).